{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T19:30:33Z","timestamp":1785007833845,"version":"3.55.0"},"reference-count":10,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypoparathyroidism is one of the few remaining hormonal insufficiencies not treated with replacement of its missing hormone. Conventional therapy involves multiple daily oral doses of calcium, active vitamin D, and magnesium, which is not only cumbersome for patients, but carries risk of nephrocalcinosis and is inadequate in patients with enteral malabsorption. Subcutaneous parathyroid hormone 1-34 (PTH[1-34]) has been tested as a hormonal replacement therapy for treatment of hypoparathyroidism. PTH(1-34) delivered by continuous infusion via insulin pump decreases or eliminates the need for oral medications, stabilizes serum and urine calcium at normal levels with minimal fluctuation, and significantly reduces PTH doses. In this case report, we describe the clinical application of PTH(1-34) via insulin pump in an adolescent with autoimmune polyendocrinopathy syndrome type 1 (APS1). Transition to a PTH pump reduced hospital admissions for calcium abnormalities and allowed our patient to discontinue all scheduled daily conventional therapy.<\/jats:p>","DOI":"10.1210\/jcemcr\/luad136","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T16:49:07Z","timestamp":1699548547000},"source":"Crossref","is-referenced-by-count":1,"title":["Initiation of Continuous rhPTH Infusion With Insulin Pump in an Inpatient Setting"],"prefix":"10.1210","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5162-0988","authenticated-orcid":false,"given":"Faith","family":"Lindsay Mart","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Cincinnati Children's Hospital Medical Center , Cincinnati, OH 45229 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8261-5188","authenticated-orcid":false,"given":"Karen K","family":"Winer","sequence":"additional","affiliation":[{"name":"National Institute of Child Health and Human Development, National Institutes of Health , Bethesda, MD 20817 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Cincinnati Children's Hospital Medical Center , Cincinnati, OH 45229 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8309-6321","authenticated-orcid":false,"given":"Halley","family":"Wasserman","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Cincinnati Children's Hospital Medical Center , Cincinnati, OH 45229 , USA"},{"name":"Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"2023121603003751300_luad136-B1","doi-asserted-by":"crossref","first-page":"723532","DOI":"10.3389\/fped.2021.723532","article-title":"Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"9","author":"Ferre","year":"2021","journal-title":"Front Pediatr"},{"issue":"12","key":"2023121603003751300_luad136-B2","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/jbmr.4716","article-title":"Management of hypoparathyroidism","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6228","key":"2023121603003751300_luad136-B3","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/bmj.280.6228.1340","article-title":"Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial","volume":"280","author":"Reeve","year":"1980","journal-title":"Br Med J"},{"issue":"8","key":"2023121603003751300_luad136-B4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"2023121603003751300_luad136-B5","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"issue":"11","key":"2023121603003751300_luad136-B6","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jc.2011-1359","article-title":"Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism","volume":"96","author":"Linglart","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2023121603003751300_luad136-B7","doi-asserted-by":"crossref","first-page":"115977","DOI":"10.1016\/j.bone.2021.115977","article-title":"Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center","volume":"149","author":"Winer","year":"2021","journal-title":"Bone"},{"issue":"6","key":"2023121603003751300_luad136-B8","doi-asserted-by":"crossref","first-page":"K13","DOI":"10.1530\/EJE-20-0710","article-title":"Recombinant human parathyroid hormone (1-84) is effective in CASR-associated hypoparathyroidism","volume":"183","author":"Hawkes","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023121603003751300_luad136-B9","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40271-019-00388-5","article-title":"Assessing the patient experience of hypoparathyroidism symptoms: development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom)","volume":"13","author":"Brod","year":"2020","journal-title":"Patient"},{"issue":"1","key":"2023121603003751300_luad136-B10","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/6\/luad136\/54078475\/luad136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/1\/6\/luad136\/54078475\/luad136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T03:00:57Z","timestamp":1702695657000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luad136\/7378279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11,3]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luad136","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11]]},"article-number":"luad136"}}